A Real-World Data Landscape Review of the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Conference

Ellen Thiel¹, Andy Surinach¹

¹Genesis Research Group, Hoboken, NJ

Introduction

- Research presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe conferences and published in the society's journal, *Value in Health*, offer insight into real-world data (RWD) use in the life sciences industry.
- A large proportion of abstracts submitted to the ISPOR family of conferences utilize a variety of RWD sources to generate real-world evidence.
- Regulators continue to sharpen guidance on realworld evidence, including fit-for-purpose data selection; therefore, it is important to describe the current real-world data landscape.

Objective

To quantify and characterize RWD sources utilized for research described in 2023 ISPOR Europe abstracts

Methods

Data Source

• The *Value in Health* December 2023 supplemental issue, which includes all ISPOR Europe 2023 conference abstracts, served as the source of research abstracts.

Research Abstract Sample

- To identify the subset of abstracts describing RWD utilization, abstracts were filtered based on a case insensitive text search of their 'Methods' sections.
- Abstracts were included if methods described direct analysis of RWD (i.e., excluding literature reviews) and identified a RWD source either by name or RWD source category.

Search Terms

"database", "data base", "real world", "real-world", "claims", "electronic health", "real-world data", "linked", "token", "survey", "registry", "electronic medical", "ehr", "emr"

- Abstracts that contained these search terms were included in the sample for additional manual review by two reviewers.
- Reviewers documented the RWD source characteristics from each abstract including:
 - RWD Source Name
 - RWD Source Type (e.g., administrative claims)
 - Country/Countries included (if data from >1 country was cited, all countries mentioned were included in the measure for figure 3)
 - Tokenized / Linked Data Source (e.g., claims+EHR)

Statistical Analyses

 Abstract characteristics were summarized with descriptive statistics

Results

 Among the 2,409 ISPOR abstracts presented at ISPOR Europe 2023, 903 (37%) mentioned utilization of RWD, and 438 met inclusion criteria for RWD source description Figure 1

Figure 1. Research Abstract Selection

Abstracts published in *Value in Health*December 2023 Supplemental issue N = 2,409

Abstracts with terms indicative of RWD use N = 903

Abstracts with clearly defined RWD sources N = 438




cited in the N=438 abstracts

• A total of 170 unique RWD sources were


ISPOR Europe abstracts

Figure 2. RWD Sources Utilized for Research in ISPOR Europe 2023 Abstracts by Type



- The most common RWD source type utilized for research was administrative claims (N=192 abstracts [44%]) Figure 2
- A total of 15 (3.4%) abstracts cited utilizing multiple RWD sources, for example: combination of administrative claims with survey data

Figure 3. Putting the "I" in ISPOR: RWD Sources by Geography



- The majority of RWD sources included data from from the U.S. (N=110 abstracts; 25.1%)
- Half of the abstracts utilized data from at least one European country (N=219 abstracts; 50%);
- Many abstracts used RWD from EU5 countries: France (n=74), United Kingdom (n=60); Germany (n=59), Italy (n=41), Spain (n=40) Figure 3

Limitations

- Our search terms may have omitted nonstandard RWD sources from the manually reviewed abstract sample.
- Descriptions of the RWD sources and/or specific data source names may have been abbreviated due to abstract word limits.

Disclosures

This study was conducted by Genesis Research Group and AS is an employee of Genesis Research Group. ET was an employee of Genesis Research Group when the research was completed.

Conclusions

- The current RWD data landscape is welldeveloped with hundreds of sources, each having unique strengths and characteristics.
- Administrative claims remain the most utilized source; however, claims alone may not be fit for all research questions.
- A data-agnostic strategy and updated knowledge of the global data landscape are beneficial for selecting fit-for-purpose RWD.



